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ABSTRACT: Mesenchymal stem cells (MSCs) are an attractive cell source for regenerative medicine. However, 
MSCs age rapidly during long-term ex vivo culture and lose their therapeutic potential before they reach effective 
cell doses (ECD) for cell therapy. Thus, a prerequisite for effective MSC therapy is the development of cell culture 
methods to preserve the therapeutic potential during long-term ex vivo cultivation. Resveratrol (RSV) has been 
highlighted as a therapeutic candidate for bone disease. Although RSV treatment has beneficial effects on bone -
forming cells, in vivo studies are lacking. The current study showed that long-term (6 weeks from primary culture 
date)-cultured MSCs with RSV induction retained their proliferative and differentiation potential despite 
reaching ECD. The mechanism of RSV action depends entirely on the SIRT1-SOX2 axis in MSC culture. In a rat 
calvarial defect model, RSV induction significantly improved bone regeneration after MSC transplantation. This 
study demonstrated an example of efficient MSC therapy for treating bone defects by providing a new strategy 
using the plant polyphenol RSV. 
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Mesenchymal stem cells (MSCs) have the capacity for 
self-renewal and differentiation into bone, adipose tissue, 
and cartilage [1]. Thus, they have been widely used to 
treat skeletal diseases including osteogenesis imperfecta 
[2, 3] and osteoarthritis [4, 5]. For clinical application, it 
is necessary to expand these cells into therapeutic doses 
for several passages in vitro because the cell numbers 
obtained directly from patients are too small for clinical 
applications. In addition, MSCs undergo cellular  
senescence with telomere shortening and lose their stem 
cell characteristics during expansion in vitro [6-8]. 
Therefore, a major challenge to the therapeutic use of 
MSCs is maintaining their self-renewal capacity and 
multipotency during long-term in vitro cultivation to 
reach effective cell doses required for clinical application. 
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 Resveratrol (RSV) is a naturally occurring 
polyphenolic compound with beneficial biological effects 
such as antiaging [9], antioxidant [10], and bone 
protective activities [11], indicating its potential as a 
therapeutic candidate. We previously optimized methods 
for culturing MSCs in vitro with RSV such as the 
concentration and duration of RSV treatment and 
procedure for passaging the cells [12]. In the study, we 
further evaluated the safety and efficacy of using MSCs 
cultured with RSV for MSC therapy. Although many 
studies have reported the effects of RSV in MSCs [13-15], 
no study has confirmed the efficacy of RSV in bone 
healing in vivo. Therefore, the aim of this study was to 
examine RSV application for MSC-based therapy in the 
preclinical setting, particularly in bone regeneration. In 
this study, we confirmed that long-term treatment with 1-
μM RSV retained the proliferative and differentiation 
potential of MSCs during prolonged ex vivo culture until 
effective cell doses (ECD) were reached for cell therapy. 
We designated the MSCs reaching ECD (1 x 107 cells) as 
6w-MSCs, since it took about 6 weeks to acquire the ECD 
cell number. Transplantation of 6w-MSCs with RSV 
induction clearly enhanced the bone regeneration 
potential in a rat model with calvarial defects. Therefore, 
MSCs expanded via cell culture with RSV induction are 
an efficient cell source for stem cell therapy in 
regenerative medicine. 
 
MATERIALS AND METHODS 
 
Isolation, cultivation, and RSV treatment 
 
Bone marrow aspirates were obtained from the posterior 
iliac crests of six adult donors with the approval of 
institutional review board (IRB) of Yonsei University 
College of Medicine (IRB No. 4-2017-0232), and written 
informed consent was obtained from all patients. All 
methods were performed according to relevant guidelines 
and regulations of the institution. MSCs isolated from 
bone marrow were selected and cultured in accordance 
with published protocols [16], and their characteristics 
(i.e., positivity for CD90 and CD105, and negativity for 
CD34 and CD45) were confirmed by flow cytometry. 
MSC characteristics of the harvested cells were confirmed 
in our previous reports [16]. All MSCs used in this study 
were isolated and cultured individually. Each 
experimental result was confirmed in at least three donor 
samples as well as triplicates. MSCs were maintained in 
low-glucose Dulbecco’s modified Eagle’s medium 
(DMEM-LG; Invitrogen, Grand Island, NY, USA) that 
was supplemented with 10% fetal bovine serum (FBS; 
Gibco, Grand Island, NY, USA) and 1% antibiotic-
antimycotic solution (Invitrogen) at 37 °C in 5% CO2 
atmosphere. The cells were grown to 80% confluence, and 
then detached by incubation with 0.25% trypsin ⁄EDTA 
(Invitrogen) centrifuged at 188 g for 3 min. The cells 
collected by centrifugation were re-plated at density of 2 
x 105 cells, and subcultivation was continued until the 
number of cells reached 1 x 107 cells. The concentration 
of RSV (Sigma-Aldrich, St. Louis, MO, USA) used (1 
µM) was selected according to a previous study [12]. 
MSC cultivation was continued without freezing or 
terminating the culture until the number of cells reached 
1x107 cells. Cells were subcultured every 3 days, and then 
counted each time. At each subculturing session, 2 x 105 
MSCs were seeded onto new 10-cm2 culture dishes. The 
number of MSCs was recorded every time the cells were 
subcultured, and the numbers were accumulated until we 
had approximately 1x107 cells; after that, the cell culture 
was terminated. The period lasted for about 6 weeks. The 
passage number, which reached 1 x 107 cells, can be 
somewhat different for each MSC derived from different 
donors. Therefore, the number of each passage requiring 
1 x 107 cells has been recorded in each figure legend. 
 
Western blotting 
 
MSCs were lysed in passive lysis buffer (Promega, 
Madison, WI, USA). Protein concentrations were 
determined using Bio-Rad Protein Assay (Bio-Rad 
Laboratories, Inc., Hercules, CA, USA), and 30 mg of 
protein per lane was analyzed by 10% sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (Sigma-
Aldrich). After the proteins were transferred to 
polyvinylidene fluoride membranes, membranes were 
blocked with 5% skim milk (BD Biosciences, Sparks, 
MD, USA) or 5% BSA (Sigma-Aldrich) for 1 h at room 
temperature. Membranes were incubated for about 12 h 
with antibodies against SIRT1 (Santa Cruz 
Biotechnology, Dallas, TX, USA), SOX2 (Abcam, 
Cambridge, UK), OCT4 (Santa Cruz Biotechnology),  
NANOG (BD Biosciences), CASPASE-3 (Cell Signaling 
Technology, Danvers, MA, USA), Cleaved CASPASE-3 
(Cell Signaling Technology), P53 (Santa Cruz 
Biotechnology), P21 (Santa Cruz Biotechnology), P16 
(Abcam), and HSP90 (Santa Cruz Biotechnology), which 
served as a loading control. 
 
Colony-forming unit fibroblast assay 
 
MSCs were seeded at 1 × 103 cells in 100-mm culture 
dishes and maintained in DMEM-LG supplemented with 
20% fetal bovine serum for 12 days. The cells were fixed 
in 1:1 acetone:methanol, stained with 20% crystal violet 
solution (Merck, Darmstadt, Germany) for 10 min in the 
dark, and washed with distilled water. The colony-
forming ability of the stained cells was evaluated for three 
donors in triplicate.  
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Cell proliferation assay 
 
Proliferative capacity of 6w-MSCs was examined using 
EZ-Cytox Kit (Daeil Lab Service, Seoul, Korea). The 6w-
MSCs were seeded in 12-well culture plate at density of 1 
× 104 cells per well. DMEM-low glucose containing 10% 
FBS medium was used for maintaining cells for 7 days, 
and culture media were replaced every 2 days during 
assay periods. To measure levels of cell proliferation,  
cells were washed with PBS, and 20 μl of EZ-Cytox 
(tetrazolium salts) solution was added to each well and 
incubated at 37 °C for 4 h. After incubation, the 
conditioned media were transferred to 96-well plate. 
Absorbance was measured at 450 nm. All samples were 
tested in triplicate (n =3). 
 
Osteogenic and adipogenic differentiation 
 
The materials and methods for MSC differentiation,  
staining, and quantitative analysis were described 
previously [16]. Briefly, MSCs were seeded at 8 X 104 
cells per well in 12-well culture plates. For osteogenic 
differentiation, cells were maintained for 10 days in 
osteogenic medium [DMEM-low glucose medium 
containing 10% FBS, 1% antibiotic-antimycotic solution,  
100 nM dexamethasone (Sigma), 10 mM β-
glycerophosphate (Sigma), and 50 μg per ml ascorbic acid 
(Gibco)]. Alizarin red S staining was employed to 
determine osteogenic differentiation activity. For alizarin 
red S staining, after being fixed in ice-cold 70% ethanol, 
1 ml of freshly prepared 3% alizarin red S solution 
(wt/vol) (Sigma) was added, then incubated in the dark for 
30 minutes. For quantitative analysis of alizarin red S, 
absorbance was detected at 595 nm after destaining with 
10% cetylpyridinium chloride monohydrate (Sigma) for 
30 minutes. For adipogenic differentiation, cells were 
maintained for 10 days in adipogenic medium [DMEM-
low glucose medium containing 10% FBS, 1% antibiotic-
antimycotic solution, 1 μM dexamethasone, 0.5 mM 
isobutyltethylxanthin (Sigma), 5 μg ⁄ ml insulin (Gibco), 
and 200 lM indomethasin (Sigma)]. Oil red O staining 
was employed to determine adipogenic differentiation 
activity. To stain lipid droplets by oil red O, after being 
fixed in 10% neutral buffered formalin, 1 ml of 0.18% oil 
red O solution (Sigma) was added and incubated for 30 
minutes. For quantitative analysis of oil red O-stained 
cells, absorbance was detected at 500 nm after destaining 
with 100% isopropanol for 30 minutes. 
 
RNA interference 
 
Negative control and SIRT1 siRNAs (siRNA No. 
1137490) were purchased from Bioneer (Daejeon, South 
Korea, www.sirna.bioneer.co.kr). Negative control-sense 
siRNA targeted sequence 5′-CCUACGCCACCAAU UU 
CGU-3′, and negative control-antisense siRNA targeted 
sequence 5′-ACGAAAUUGGUGGCGUAGG-3′. SIRT1 
-sense siRNA targeted sequence 5′-CUGUGAAAU 
UACUGCAAGA(dTdT)-3′, and SIRT1-antisense siRNA 
targeted sequence 5′-UCUUGCAGUAAUUUCACA 
G(dTdT)-3′. Briefly, MSCs treated with RSV (1 μM) 
were plated to obtain 70% confluence in 6-well plates and 
transfected with 100 nM of negative control or SIRT1 
siRNA using Lipofectamine LTX (Invitrogen). After 6 h 
of transfection, growth medium was added. 
 
Immunoprecipitation 
 
Cell lysates from MSCs were prepared with non-
denaturing lysis buffer, as previously described [16]. 
Lysates were incubated with protein A/G agarose beads 
(Santa Cruz Biotechnology) and antibodies against 
acetylated lysine (Cell Signaling Technology) and SOX2 
(Abcam). Beads conjugated with both lysates and 
antibodies were collected after centrifugation and washed 
three times with lysis buffer. The complexes were 
released from beads by boiling with 2× SDS sample dye, 
and then western blotting was performed. All membranes 
were incubated with antibody against SOX2 (Abcam) for 
12 h, followed by incubation with HRP-conjugated 
secondary antibody for 1 h. 
 
Immunocytochemistry 
 
Immunostaining was performed according to our 
previously reported protocol [16]. MSCs were seeded at 2 
000 cells/cm2 on 4-well glass chamber slides (Nalge Nunc 
International, Rochester, NY, USA), and cells were 
incubated in 5% CO2 incubator at 37 °C overnight. After  
that, cells were washed with PBS, followed by fixation 
with 4% paraformaldehyde (Sigma-Aldrich) for 30 min.  
Permeabilization was accomplished with 1% Triton X-
100 in PBS for 10 min, followed by blocking with 3% 
bovine serum albumin (BSA) in PBS for 1 h. Cells were 
incubated with a 1:100 dilution of primary antibodies  
against SOX2 (Abcam), SIRT1 (Santa Cruz 
Biotechnology), and bromodeoxyuridine (Santa Cruz 
Biotechnology) overnight at 4 °C. After washing three 
times with PBS, cells were incubated with fluorescein 
isothiocyanate (FITC)-, phycoerythrin (PE, red)-, or alexa 
fluor 568 (Yellow)-conjugated secondary antibodies  
(Santa Cruz Biotechnology) at a 1:5000 dilution in PBS 
containing 1% BSA for 1 h at room temperature in the 
dark. The nuclei were stained with 4′,6-diamidino-2-
phenylindole (Sigma-Aldrich), and then examined by 
LSM780 scanning laser confocal microscope (Zen 2012; 
Carl Zeiss MicroImaging GMBH, Jena, Germany). 
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Figure 1. 6w-MSCs with RSV induction preserve the proliferative capacity even after reaching effective 
cell dose (ECD) for MSC therapy. (A) Scheme for MSC isolation and long-term cultivation to obtain ECD-
MSCs. First, 0.05% vehicle (EtOH) or 1 μM RSV was added to the medium for MSC culture and the vehicle 
or RSV-containing medium was exchanged every 2 days. The cells were cultured until vehicle-treated MSCs 
reached 1 × 107 cells, generally regarded as the ECD for bone regeneration. (B) The numbers of MSCs 
between 1–6 weeks of expansion in the absence or presence of RSV (n = 6 donors). The cells were counted 
every 7 days. (C) SA-β-gal assay was performed to compare cellular senescence between vehicle and RSV 
groups. 2w-MSCs refers to the MSCs cultured during 2 weeks from primary culture date, and 6w-MSCs 
refers to the MSCs cultured during 6 weeks from primary culture date in order to obtain 1 × 107 cells. SA-
β-gal-positive cells were quantitated by ImageJ (n = 3, in triplicate per donor) (right). *p < 0.05 compared to 
vehicle-treated MSCs. 2w-MSCs, 3rd passage; 6w-MSCs, 13th passage. (D) Immunocytochemistry was 
performed to observe the bromodeoxyuridine-positive cell portion. Nuclei were stained with 4′,6-diamidino-
2-phenylindole and images were captured by confocal microscopy. Scale bar = 100 µm. *, p < 0.05 compared 
to vehicle-treated 6w-MSCs (n = 3, in triplicate per donor). 6w-MSCs, 13th passage. (E) The proportion of 
6w-MSCs treated with vehicle or RSV in each cell cycle phase was evaluated by flow cytometry with 
propidium iodide staining. *, p < 0.05 compared to vehicle-treated 6w-MSCs (n = 3, in triplicate per donor). 
6w-MSCs, 13th passage. (F) Protein levels of P53, P21, P16, CASPASE-3, and cleaved CASPASE-3 were 
quantified by western blot analysis and normalized to that of HSP90. 2w-MSCs, 4th passage; 6w-MSCs, 13th 
passage. (G) Quantification of each protein level was determined by GraphPad Prism software (version 6.0). 
*, p < 0.05 compared to 2w- or vehicle-treated MSCs (n = 3, in triplicate per donor). 
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SOX2 overexpression 
 
Information for the SOX2 has been described 
previously[16]. Briefly, SOX2 cDNA was inserted into 
the pEGFP-C1 vector between SacI and KpnI (Takara 
Bio, Inc., Shiga, Japan) to generate pEGFPC1/SOX2, 
which expresses a green fluorescent protein (GFP)-SOX2 
fusion protein. For SOX2 overexpression, MSCs were 
plated to obtain 70% confluence in six-well plates and 
transfected with pEGFP-C1/SOX2 using Lipofectamine 
LTX (Invitrogen).  
 
Cell cycle analysis 
 
Single-cell suspension of differentiated cells was prepared 
as previously described [17]. MSCs treated with ethanol 
(vehicle) or RSV were harvested by incubation with 
0.25% trypsin/EDTA and washed twice in PBS. Cells  
from each group (1 × 106) were fixed in ice-cold 70% 
ethanol for 30 min, stained with 50 µg/ml propidium 
iodide (Sigma-Aldrich) containing 100 µg/ml RNase A 
(Sigma-Aldrich) for 15 min at 4 °C, and then analyzed 
using FACSCalibur™ instrument (BD Biosciences, San 
Jose, CA, USA) to detect the cell cycle distribution. All 
samples used were tested in triplicate (n = 3). 
 
Quantitative real-time polymerase chain reaction (qRT-
PCR) 
 
Total RNA was isolated using an RNeasy kit (Qiagen,  
Hilden, Germany). Total RNA (1 mg) was then reverse-
transcribed using an Omniscript® kit (Qiagen). 
Quantitative real-time polymerase chain reaction was 
performed as previously described [16]. Primer sets were 
validated and purchased from Bioneer 
(https://us.bioneer.com/products/rnai/rnaioverview.aspx, 
Daejeon, South Korea). The primer sets and numbers used 
were as follows: Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH, P267613), runt-related 
transcription factor 2 (RUNX2, P229954), collagen, type 
I, alpha 1 (COL1A1, P157768), peroxisome proliferator-
activated receptor gamma (PPAR-γ, P102309), 
adiponectin (APN, P160254), cyclin A (CCNA, P212796), 
cyclin D (CCND, P298560), cyclin-dependent kinase 2 
(CDK2, P136765), and cyclin E (CCNE, P220201). 
 
Senescence-associated-β-galactosidase assay (SA-β-gal 
assay) 
 
The SA-β-gal assay was performed using a cellular  
senescence assay kit (Millipore, Billerica, MA, USA) 
following the manufacturer’s instructions. Cells were 
washed with PBS, and then were fixed for 10 min at room 
temperature with 1X fixing solution. After washing with 
D.W, cells were stained with prepared 1X SA-β-gal 
detection solution over 4h in the dark at 37 °C incubator 
without CO2. The number of positive cells was quantified 
by Image J software, version 1.41 (National Institutes of 
Health, Bethesda, MA, USA). 
 
Rat calvarial defects 
 
All animal use procedures were conducted with the 
approval of the Institutional Animal Care and Use 
Committee of Yonsei University College of Medicine 
(Approval number: IACUC-2016-0099). Twelve-week-
old male Sprague–Dawley rats were anesthetized by an 
intraperitoneal injection of Zoretile (30 mg/kg body 
weight) and xylazine (10 mg/kg body weight). After 
shaving the hair on the head, a longitudinal incision was 
made in the skull, and then critical-sized calvarial bone 
defects with a diameter of 8 mm were created using a 
trephine bur. The defects were irrigated with saline and 
MSCs (1 × 106/defect) mixed with fibrin glue were 
implanted into the defects, followed by suturing of the soft 
tissue. For pain relief, rats were administered a 
subcutaneous injection of meloxicam (0.2 mg/kg body 
weight). At 4–8 weeks after operation, all rats tested were 
sacrificed and the skull was harvested for micro-computed 
tomography (µCT) and histological analysis (n = 10 per a 
group). 
 
µCT analysis 
 
After fixation in 10% formalin for 5 days, the skulls were 
scanned with a high-resolution µCT instrument (SkyScan 
1076; Bruker, Billerica, MA, USA) to quantitatively 
evaluate calvarial bone regeneration at the defect site as 
described previously[18]. Briefly, the imagery was 
reconstructed and analyzed using NRecon v1.6.6.0 and 
CTAn v1.13.2.1 (Bruker), respectively. Three-
dimensional model visualization software CTVol v2.0 
(Bruker) was used to analyze calvarial bone regeneration. 
The settings for X-ray source were 70 kVp voltage and 
140 mA current, and 0.5-mm-thick aluminum filter was 
used for beam induration. Pixel size was 18 mm, exposure 
time was 1475 ms, and rotation step was 0.5°, with a 
complete rotation through 360°. 
 
Histological analysis and immunohistochemistry 
 
The skulls were fixed for 1 week in 10% formalin and then 
embedded in paraffin. The paraffin-embedded sections 
were deparaffinized, rehydrated, and washed three times 
with PBS, and then the sections were used to evaluate 
tissue repair in the damaged regions. Histological analysis  
and immunohistochemistry were performed as previously 
described[18]. Briefly, tissue samples were sliced at a 
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thickness of 4 µm and stained with hematoxylin and eosin 
(H&E) to observe new bone formation or incubated with 
human anti-vimentin antibodies (Santa Cruz 
Biotechnology, 1:100 dilution) to confirm whether the 
regenerated bone tissues were derived from human origin.  
Human vimentin was detected with a secondary goat anti-
mouse IgG-horseradish peroxidase antibody 
(GenDEPOT, Katy, TX, USA) and 3,3′-diaminobenzidine 
(Vector Laboratories, Burlingame, CA, USA). The 
stained samples were observed using VS120 virtual 
microscope (Olympus, Tokyo, Japan), and sample images 
were analyzed using OlyVIA 2.5 software (Olympus). For 
immunofluorescence, paraffin-embedded tissue sections 
with a thickness of 4 µm were deparaffinized, 
 
 
 
 
 
Figure 2. Long term-cultured MSCs with RSV induction preserve the self-renewal and multi-differentiation capacities even 
after reaching ECD for MSC therapy. (A) 2w- and 6w-MSCs (1 × 103 cells per well in 100-mm dishes) treated with vehicle or RSV 
were incubated in growth medium for 12 days. The colony-forming abilities of the cells were compared by crystal violet (CV) staining. 
The colony number was counted by three independent observers (n = 3, in triplicate per donor). *, p < 0.05. 2w-MSCs, 2nd passage; 
6w-MSCs, 14th passage. (B) Alizarin red S staining was performed to detect mineral deposition and was quantified with ImageJ software 
(n = 3, in triplicate per donor). *, p < 0.05 compared to vehicle. 2w-MSCs, 2nd passage; 6w-MSCs, 14th passage. (C) The mRNA 
expression of RUNX2 and COL1A1 was determined in 2w- or 6w-MSCs treated with 0.05% vehicle (EtOH) or 1-μM RSV by real-time 
quantitative PCR (n = 3, in triplicate per donor). *, p < 0.05 compared to vehicle. 2w-MSCs, 3rd passage; 6w-MSCs, 14th passage. (D) 
Oil red O staining was performed to detect lipid droplets and were quantified with ImageJ software (n = 3, in triplicate per donor). *, p 
< 0.05 compared to vehicle. 2w-MSCs, 2nd passage; 6w-MSCs, 14th passage. (E) The mRNA expression of PPARγ and ADIPONECTIN 
was determined in 2w- or 6w-MSCs treated with 0.05% vehicle (EtOH) or 1-μM RSV by real-time quantitative PCR (n = 3, in triplicate 
per donor). *, p < 0.05 compared to vehicle. 2w-MSCs, 3rd passage; 6w-MSCs, 14th passage. 
  
Choi Y., et al                                                                                             MSC-Driven Bone Healing by RSV Treatment 
Aging and Disease • Volume 10, Number 4, August 2019                                                                               824 
 
rehydrated, and washed twice with PBS. To reduce 
nonspecific background staining due to endogenous 
peroxidase, sections were incubated in hydrogen peroxide 
blocks for 10 min and washed twice with PBS. Sections 
were incubated with SIRT1 (Abcam), SOX2 (Abcam), 
RUNX2 (Millipore), or OSTEOCALCIN (Abcam) 
antibodies with human VIMENTIN antibody (Santa Cruz 
Biotechnology) overnight at 4 °C, and then washed with 
PBS. Phycoerythrin-conjugated goat anti-rabbit 
secondary antibodies (Santa Cruz Biotechnology) and 
FITC-conjugated goat anti-mouse secondary antibodies 
were used to visualize the primary antibodies. All primary 
and secondary antibodies were applied at dilutions of 
1:100 and 1:5000, respectively. The nuclei were stained 
with 4′,6-diamidino-2-phenylindole (DAPI, Sigma). 
Images were examined using Zeiss LSM 700 confocal 
laser scanning microscope (ZEN 2012 software; Carl 
Zeiss Micro Imaging GmbH, Jena, Germany). 
 
Chromosomal abnormality assay 
 
To analyze chromosome instability, 20 cells at metaphase 
per sample were counted after staining. For karyotyping, 
at least 10 more cells at metaphase were analyzed and 
images were captured. GTG-(Giemsa-Trypsin)-banding 
with 525 bands of resolution was performed by 
Samkwang medical laboratories (www.smlab.co.kr/).  
 
In vivo tumorigenicity assay 
 
To evaluate in vivo tumorigenicity, MSC, RSV-MSC and 
NKM-74 cells (5 × 106) were suspended in 200 µL of PBS 
containing 20% Matrigel (Sigma), and subcutaneously 
injected into Balb/C/nu/nu mice (Orient Bio, Inc., 
Seongnam, Korea). One or five months after implantation,  
tumor dimensions were determined with a caliper, and the 
volumes were calculated using the following formula: 
Tumor volume = π/6 × length × width × height [19]. 
Length represents the largest tumor diameter, and width 
represents the perpendicular tumor diameter. 
 
Statistical analyses 
 
To determine the differences between two groups, 
Student’s t-tests were performed. For more than two 
groups, one-way analysis of variance was performed if 
normality tests passed, followed by Tukey’s multiple 
comparison tests for all pairs of groups. The data are 
presented as the mean ± standard deviation. All 
experiments were conducted in triplicate. GraphPad 
Prism software (version 6.0; GraphPad, La Jolla, CA, 
USA) was used for statistical analysis. Values of p < 0.05 
were considered statistically significant. 
 
RESULTS 
RSV allows mass production of MSCs with effective 
cell doses (ECD) 
The marrow mixture was isolated and seeded onto a 
culture plate to allow the MSCs to attach the plastic 
culture dish. Attached cells were divided into groups 
treated with 0.05% vehicle or 1 μM RSV and cultured 
until vehicle-treated MSCs reached an ECD (1 x 107 cells)  
(Fig. 1A). There have been many clinical trials using 
MSCs to treat small or critical bone defects[20]. A 
minimum number of cells is required to obtain a 
successful therapeutic effect following MSC 
implantation. To date, there is no standard ECD for 
treating bone defects, but a minimum of 1 x 107 cells  
appears to be required for treating bone defects (See 
supplementary Table 1). Thus, we grew control MSCs 
treated with vehicle to 1 x 107 cells, and then compared 
the obtained cell amounts with RSV-treated MSCs. In the 
absence of RSV, the cell number reached more than 1 × 
107 at about 6 weeks, whereas in the presence of RSV, the 
cell number was approximately 1 x 107 at about 4 weeks. 
Indeed, at 6 weeks, the number of MSCs cultured in the 
presence of RSV (5.82 ± 0.92 × 107) was approximately 
4-fold higher than that of MSCs cultured in the absence of 
RSV (1.31 ± 0.29 × 107) (Fig. 1B, supplementary Table 
2). We designated these cells as 6w-MSCs (MSCs with an 
effective cell dose for bone regeneration) and used the 
cells for further experiments. It took about 2 weeks to 
obtain a sufficient number of young MSCs for further 
experiments. Although these young MSCs were not 
suitable for in vivo experiments due to the limited number 
of cells, they were sufficient for further in vitro 
experiments. Therefore, we also designated them as 2w-
MSCs (not effective dose for in vivo bone regeneration,  
but appropriate cell number for in vitro test), and used the 
cells as control groups of 6w-MSCs. We next compared 
the degree of cellular senescence between vehicle- and 
RSV-treated 6w-MSCs by SA-β-galactosidase (SA-β-gal)  
staining. RSV alleviated the level of cellular senescence 
compared to that of its counterpart (Fig. 1C). In addition, 
the proportion of bromodeoxyuridine-positive cells was 
higher in 6w-MSCs with RSV induction than in its 
counterpart (Fig. 1D). Moreover, the cell populations of 
control 6w-MSCs in S phase were smaller than those of 
6w-MSCs with RSV induction (Fig. 1E). The expression 
of cell cycle-related genes CCNA, CCND, CDK2, and 
CCNE, which are associated with S phase [21, 22], was 
higher in 6w-MSCs with RSV induction compared to in 
control 6w-MSCs (Supplementary Fig. 1). However, the 
results of SA-β-gal assay and cell cycle analysis cannot 
fully explain the higher rate of growth by RSV treatment 
in MSC culture. To address this phenomenon more 
clearly, we checked the protein level of CASPASE-3, 
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Figure 3. RSV treatment stabilizes SOX2 protein levels in MSCs depending on the presence of SIRT1. (A) 
Expected model of the mechanism of RSV action on the regulation and maintenance of MSC stemness via SIRT1-
SOX2 axis. (B) Protein levels of SIRT1, SOX2, OCT4, and NANOG were quantified by western blot analysis and 
normalized to that of HSP90. (C) Quantitative analysis of SOX2 protein was performed by ImageJ software (n = 3, 
in triplicate per donor). *, p < 0.05, ns; not significant compared to control. MSCs of 4th passage were used for this 
western blot. (D) Immunoprecipitation was conducted in the presence of MG132. To confirm acetylated-lysine and 
SOX2, each protein was immunoprecipitated using antibodies targeting each protein followed by western blotting 
using an anti-SOX2 antibody (n = 3, in triplicate per donor). All study groups were treated with MG132 (10 µM), 
a proteasome inhibitor. MSCs of 4th passage were used for immunoprecipitation. (E) Immunocytochemistry was 
conducted to observe cellular localization of SOX2 from the nucleus to the cytoplasm, following SIRT1 knockdown 
in the presence of RSV (n = 3, in triplicate per donor). To inhibit proteasomal degradation of SOX2, all study groups 
were treated with MG132 (10 µM). Nucleus was stained with DAPI, and images were captured by confocal 
microscopy. Red arrowhead indicates nuclear exports of SOX2 protein. Scale bar = 50 μm. MSCs of 4th passage 
were used for immunocytochemistry. (F) Efficiency of SIRT1 knockdown or SOX2 overexpression was confirmed 
by western blot analysis in MSCs (n = 3, in triplicate per donor). MSCs of 4th passage were used for this western 
blot. (G) Colony-forming cells were detected by CV staining, and (H) the number was counted by three observers 
(lower panel) (n = 3, in triplicate per donor). *, p < 0.05. Alizarin red S (I) and oil red O (J) staining was conducted 
to compare mineralization and accumulation of lipid droplets. (K) Quantitative analysis for mineralization was 
measured at 595 nm absorbance (lower panel). *, p < 0.05. Lipid droplets were quantified with ImageJ software (n 
= 3, in triplicate per donor). Scale bar = 60 µm. *, p < 0.05. MSCs of 12th passage were used for CV, alizarin red 
S, and oil red O stains. 
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which is known as a family of endoproteases that provide 
critical links in cell regulatory networks controlling the 
cell cycle, cell proliferation, and anti-apoptotic capacity 
of MSCs[23]. We also checked the protein levels of 
markers that are related to the cell cycle and potential 
cellular senescence, such as P53, P21, and P16[24]. In our 
results, RSV treatment prevented 6w-MSCs from 
cleavage of CASPASE-3 protein as well as accumulation 
of cell cycle inhibitors (Fig. 1F, 1G), indicating that there 
were more proliferating and healthy cells in 6w-MSCs 
with RSV induction than in control 6w-MSCs. 
6w-MSC with RSV induction retain self-renewal and 
multipotency over multiple passages 
The colony-forming unit fibroblast assay showed that 6w-
MSCs with RSV induction retained their colony-forming 
abilities compared to control 6w-MSCs (Fig. 2A). To 
compare multipotency, we induced osteogenic and 
adipogenic differentiation of MSCs. As expected, 6w-
MSCs with RSV induction maintained their potential for 
osteogenic and adipogenic differentiation. Alizarin red S 
staining showed that osteogenic differentiation was 
significantly more pronounced in 6w-MSCs with RSV 
induction compared to in control 6w-MSCs (Fig. 2B). The 
mRNA levels of RUNX2 and Collagen Type I Alpha 1 
(COL1A1) were also highly expressed in 6w-MSCs 
treated with RSV (Fig. 2C). The 6w-MSCs with RSV 
induction also maintained their ability to differentiate into 
the adipogenic lineage. Oil red O staining showed that 
6w-MSCs treated with RSV formed lipid droplets more 
frequently than control 6w-MSCs upon adipogenic  
induction (Fig. 2D). The mRNA levels of PPARγ and 
Adiponectin (APN) were also highly expressed in 6w-
MSCs treated with RSV (Fig. 2E). To test a possibility 
that SOX2 overexpression solely regulated the self-
renewal and multipotency of 6w-MSCs independently of 
RSV-mediated signaling, we compared the effect of 
single SOX2 overexpression with its counterpart (pEGFP-
C1 vector only) with or without RSV. SOX2 
overexpression enhanced the proliferative capacity of 
vector control MSCs, and RSV synergistically increased 
the proliferative capacity of MSCs overexpressing SOX2 
(supplementary Fig. 2A and 2B). Likewise, RSV 
enhanced the osteogenic and adipogenic potentials of 6w-
MSCs overexpressing SOX2 (supplementary Fig. 2C-2F), 
which implies that RSV and SOX2 may have a synergistic 
effect in MSC self-renewal and multipotency. These data 
suggest that 6w-MSCs with RSV induction retain their 
self-renewal capacity and multipotency during ex vivo 
expansion over multiple passages. 
 
SIRT1 and SOX2 are required for 6w-MSCs with RSV 
induction to maintain stemness 
 
We previously reported that SIRT1 positively regulated 
SOX2 to maintain the stemness of early passage-MSCs 
and RSV-induced enhancement of MSC proliferation and 
differentiation was largely dependent on the presence of 
SOX2[16]. However, we did not determine whether RSV-
mediated SOX2 overexpression depends on SIRT1 in the 
study (Fig. 3A). To clarify whether RSV-mediated SOX2 
activation requires SIRT1, SIRT1 was knocked down in 
RSV-treated MSCs and then western blot analysis was 
performed. The results showed that the SOX2 protein 
level increased by RSV treatment was significantly 
reduced in the SIRT1 RNAi group, while the levels of 
OCT4 and NANOG, known to be important regulators for 
maintaining MSC stemness, were not altered by RSV 
treatment or SIRT1 RNAi (Fig. 3B, 3C). SIRT1 physically 
interacts with SOX2 protein to deacetylate and prevent 
nuclear export of the protein[16]. This mechanism is well-
conserved in mouse somatic reprogramming[25]. We 
confirmed that RSV induced deacetylation of SOX2 and 
SIRT1 RNAi abolished the RSV-mediated effect on 
SOX2 protein (Fig. 3D). Additionally, SIRT1 RNAi 
induced nuclear export of SOX2 under RSV stimulation 
(Fig. 3E). To confirm whether RSV-mediated SOX2 
activation requires SIRT1 as an intermediator and is  
important for enhancing MSC stemness, we used the 
pEGFP-C1 SOX2 vector to express SOX2-GFP in the 
presence of RSV and SIRT1 RNAi (Fig. 3F). As a result, 
RSV enhanced MSC self-renewal and multi-potency, 
while SIRT1 RNAi completely abolished the RSV effects 
(Fig. 3G–3K). As expected, SOX2 overexpression 
rescued the effects of SIRT1 RNAi in the presence of RSV 
(Fig. 3G–3K). These results indicate that SIRT1 acts as an 
intermediator of RSV-mediated SOX2 activation, and the 
SIRT1-SOX2 axis is critical for the RSV-mediated 
benefit in maintaining MSC stemness. 
 
RSV induction preserves nuclear levels of SIRT1 and 
SOX2 proteins during 6w-MSC proliferation and 
differentiation  
SOX2 plays a critical role in the improvement of cell 
proliferation and multipotency, and preserving SOX2 
expression in MSCs can be a useful method for 
maintaining MSC population with stemness for long-term 
culture periods [26-29]. To confirm whether RSV-
mediated maintenance of the self-renewal and 
multipotency of 6w-MSCs are due to the preservation of 
SIRT1-mediated SOX2 expression, we performed 
immunocytochemistry against SIRT1 and SOX2 during 
the proliferation and differentiation of 6w-MSCs. The 6w-
MSCs were maintained in vehicle- or RSV-containing 
basal growth medium for 10 days, and then 
immunostaining against SIRT1 and SOX2 was performed 
to compare the levels of both proteins. Our results showed 
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that in 6w-MSCs grown with vehicle-containing medium, 
the levels of SIRT1 and SOX2 were much weaker than in 
those grown with RSV-containing medium on Day 1, and 
both proteins were almost not detected from Day 4 to Day 
10. In 6w-MSCs grown with RSV-containing medium,  
the levels of SIRT1 and SOX2 were much higher than 
those grown with vehicle-containing medium on Day 1, 
and although the levels gradually decreased over 10 days, 
both protein levels were still maintained from Day 4 to 
Day 10 (Fig. 4A). Likewise, the levels of SIRT1 and 
SOX2 were maintained higher during osteogenic and 
adipogenic differentiation when 6w-MSCs were cultured 
in RSV-containing differentiation media (Fig. 4B, 4C). 
These results indicate that MSCs with high differentiation 
potential can be obtained for clinical purposes, since RSV 
treatment allows MSCs to maintain high levels of SIRT1 
and SOX2 during long-term in vitro cultivation.  
 
Figure 4. Time-course patterns of RSV-mediated SIRT1-SOX2 regulation in 6w-MSCs. (A) Immunofluorescence 
was performed to observe the time course patterns of RSV-mediated SIRT1-SOX2 regulation in the vehicle- and RSV-
treated 6w-MSCs cultured under basal DMEM -low glucose medium containing 10% FBS and 1% antibiotic and 
antimycotic. SIRT1 and SOX2-stained cells were analyzed using Image J software. (B) Immunofluorescence was 
performed to observe the time course patterns of RSV-mediated SIRT1-SOX2 regulation in the vehicle- and RSV-
treated 6w-MSCs cultured under osteogenic medium. SIRT1 and SOX2-stained cells were analyzed using Image J 
software. (C) Immunofluorescence was performed to observe the time course patterns of RSV-mediated SIRT1-SOX2 
regulation in the vehicle- and RSV-treated 6w-MSCs cultured under adipogenic medium. SIRT1 and SOX2-stained 
cells were analyzed using Image J software. The nucleus was stained with DAPI, SIRT1was stained with phycoerythrin 
(PE, red)-conjugated secondary antibody, and SOX2 was stained with alexa fluor 568 (Yellow)-conjugated secondary 
antibody. Scale bar=10 μm. 6w-MSCs of 11th passage were used for this immunofluorescence. 
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Figure 5. RSV induction improves bone healing potential of 6w-MSCs. (A) Critical-sized calvarial defects (8-mm diameter) in 
rats were covered with fibrin glue, except for defect control treatment. Eight weeks after implantation, bone regeneration was 
measured by micro-computed tomography. A representative image is shown. (B) This graph shows the bone volume per mm3 (right 
panel) (n = 10). *, p < 0.05 compared to defect. #, p < 0.05 compared to 6w-MSCs treated with vehicle. (C) Hematoxylin and eosin 
staining was performed to observe new bone formation. The arrows show the edges of the host bone and line with asterisks indicates 
newly regenerated bone. Scale bar = 500 μm. (D) To confirm whether the newly regenerated bone was derived from a human origin, 
immunohistochemistry was performed using antibodies specific to human vimentin. The arrows indicate tissue derived from a human 
origin. Scale bar = 20 μm. (E) To confirm whether the transplanted 6w-MSCs contributed to bone regeneration of calvarial defects, 
immunohistochemistry was performed using antibodies against SIRT1, SOX2, RUNX2, and OCN as well as antibodies specific to 
human vimentin. The nucleus was stained with DAPI, and human VIMENTIN was stained with FITC-conjugated secondary antibody. 
SIRT1, SOX2, RUNX2, and OCN were stained with phycoerythrin (PE, red)-conjugated secondary antibody. Scale bar = 50 μm. (F) 
Effect of 6w-MSCs with RSV induction on tumorigenicity in 5-week-old female BALB/C nude mice. (G) Effect on the growth of 
MKN-74 cells, 6w-MSCs with vehicle induction, and 6w-MSCs with RSV induction xenografted in nude mice, showing no tumor 
growth in both 6w-MSC groups. (H) G-banding chromosome karyotype from 6w-MSCs with vehicle or RSV induction for 6 weeks. 
6w-MSCs with 12th to 14th passages were used for animal experiments. 
RSV induction enhances 6w-MSC-driven bone 
regeneration 
To address the clinical potential of RSV in MSC-driven 
bone regeneration, we investigated the regenerative 
potential of 6w-MSCs transplanted in a rat calvarial defect 
model. Critical size calvarial defects (8 mm diameter)  
were created and covered with fibrin glue mixed with the 
cells. At 4 weeks after implantation, micro-computed 
tomography analysis showed that bone regeneration was 
slightly increased in both 6w-MSCs with or without RSV 
induction (Supplementary Fig. 3). Eight weeks post-
surgery, 6w-MSCs with RSV induction showed 
dramatically enhanced bone regeneration displayed by a 
better bone volume filled with mineralized bone 
compared to vehicle-treated MSCs (Fig. 5A, 5B). At 8 
weeks post-transplantation, the bone bridge nearly filled  
with the defect in 6w-MSCs with RSV induction, whereas 
partially regenerated bone was observed in 6w-MSCs 
treated with vehicle (Fig. 5C). Immune response by 
allogenic cell transplantation to the recipient can be an 
important issue in clinical trials. Bone marrow-derived 
MSCs are known to have immune suppressive effects. 
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Some reports have shown that MSCs suppress 
alloreactive T cells depending on cell doses [30], and do 
not elicit lymphocyte proliferation response [31]. In 
addition, MSCs can modulate immune responses at 
multiple levels by inhibiting the generation and function 
of monocyte-derived dendritic cells [32]. Recent studies 
showed no obvious immune response and inflammatory 
cells in animal tissues grafted with human MSCs [33, 34], 
thereby inducing successful tissue regeneration by MSCs 
without inflammation. In the current study, we also did 
not observe immune rejection responses, such as 
macrophage production, in rat calvarial tissues 
xenografted by human 6w-MSCs. Our results are in line 
with those of previous studies, indicating that MSCs have 
immune-modulatory effects in xenograft models. To 
confirm whether newly regenerated bone is derived from 
MSCs implanted in vivo, we performed immune-
histochemistry using an antibody against human-specific 
vimentin, a marker of mesenchymal-derived cells because 
transplanted MSCs were of human origin[35]. Positive 
staining for human vimentin revealed that newly 
regenerated bone originated in implanted human MSCs 
(Fig. 5D). To explain this discrepancy on why 6w-MSCs 
treated with RSV had a greater bone regenerative property 
than that of control 6w-MSCs, we performed 
immunostaining against each SIRT1, SOX2, RUNX2, 
and OSTEOCALCIN (OCN), and they were cross-stained 
with human VIMENIN. RUNX2 is a major transcription 
factor of osteogenic differentiation, and OCN plays an 
essential role for the maturation of mineral formation [36]. 
Our results showed that in 6w-MSCs treated with RSV,  
human VIMENTIN-positive cells still retained SIRT1 and 
SOX2. In addition, levels of RUNX2 and OCN in RSV-
treated 6w-MSC group were higher than those of control 
group and were positive to human VIMENTIN (Fig. 5E). 
Human VIMENTIN was not detected in groups with no 
human MSCs (supplementary Fig. 4). These results 
indicate that implanted human 6w-MSCs directly 
contribute to bone regeneration. To test the safety of long-
term culture 6w-MSCs with RSV induction for MSC 
therapy, we analyzed the surface markers of MSCs, 
identified by the International Society for Cell Therapy 
[37], using flow cytometry in the absence or presence of 
RSV. All 6w-MSCs stably expressed CD90 and CD105, 
which are positive surface markers of MSCs, whereas the 
cells were negative for CD34 and CD45 (Supplementary 
Fig. 5), indicating that RSV induction did not alter the 
surface antigen profiles of MSCs. For in vivo 
tumorigenicity, 6w-MSCs with or without RSV induction 
were subcutaneously implanted into nude mice. We also 
injected MKN-74 cells, which are gastric adenocarcinoma 
cells, into nude mice as a positive control. As a result, 
MKN-74 adenocarcinoma cells formed tumors with a 
volume of 2.8 ± 1.2 cm3 by 28 days, whereas 6w-MSCs 
with or without RSV induction did not form visible 
tumors after 150 days (Fig. 5F, 5G). In the field of stem 
cell-based regenerative medicine, genetic instability that 
appears in stem cells during ex vivo manipulation such as 
in vitro expansion, culture condition, and transgenics [38], 
thus resulting in tumorigenesis after in vivo implantation 
of stem cells, is a major limitation to application of this 
method [39]. Therefore, we tested the chromosomal 
instability of MSCs in a G-banding karyotyping assay to 
analyze chromosomal aberrations. Both 6w-MSCs 
contained the first 22 pairs of chromosomes, known as 
autosomes, and sex chromosomes (XY). Additionally, 
there were no structural abnormalities in these 
chromosomes (Fig. 5F). These results indicate that RSV 
treatment does not lead to chromosome instability and 
tumor formation in MSCs, indicating that 6w-MSCs with 
RSV induction are safe for clinical application. In 
conclusion, we demonstrated the possibility of using 6w-
MSCs with RSV induction for stem cell therapy which 
showed sufficient efficacy and safety for clinical 
application. There are several potential benefits to using 
RSV as an additive to MSC cultures, including the faster 
acquisition of a sufficient number of cells, easy treatment 
procedure, high efficacy of differentiation, and no 
genotoxicity. This method overcomes the major 
limitations to clinical application of MSCs in tissue 
regeneration. 
 
DISCUSSION 
 
MSCs are used for skeletal tissue engineering, but they 
typically lose their stem cell characteristics during in vitro 
expansion, which is a necessary step to obtain a sufficient 
number of cells for disease treatment [6, 7, 40]. For the 
development of stem cell therapy, it is important for 
MSCs to maintain their stem cell features during long-
term in vitro expansion. In addition, genotoxicity must be 
considered because it is possible for stem cells maintained 
in vitro to generate tumors when they are transplanted in 
vivo [41]. Herein, we report the possibility that MSCs 
expanded in culture with RSV can be used for stem cell 
therapy and have sufficient efficacy and safety for clinical 
application. There are several potential benefits to using 
RSV as an additive for MSC cultures, including the faster 
acquisition of a sufficient number of cells, an easy 
treatment procedure, a high efficacy of differentiation,  
and no genotoxicity. These results can eliminate major 
obstacles for the clinical application of MSCs in tissue 
regeneration. RSV is a natural polyphenol compound that 
is well-known as a potent SIRT1 activator and has been 
reported to have beneficial effects against aging and 
various human diseases including cancer [41, 42]. Our 
previous studies revealed that SIRT1, which functions as 
an NAD+-dependent lysine deacetylase, prevents SOX2 
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against degradation by deacetylating it, thus maintaining 
the stemness of MSCs after extended passaging [16]. 
Indeed, RSV could retain the self-renewal and multi-
lineage differentiation capacities of human MSCs beyond 
passage 10 through a SIRT1-dependent pathway [12, 16]. 
Additionally, SIRT1 indirectly regulates the expression of 
OCT4 and NANOG, which is normally suppressed by P53, 
by deacetylating P53 in human embryonic stem cells and 
cancer stem cells [43, 44], while RSV was reported to 
reduce the protein level of P53 through inducing its 
deacetylation in adult stem cells [45]. In agreement with 
these reports, Figure 3b showed that the protein level of 
SOX2 and NANOG were almost entirely retained in 
RSV-treated MSCs. However, the protein of OCT4 did 
not significantly change. Previous studies have reported 
that OCT4 is dispensable for the maintenance of the self-
renewal ability in somatic cells [46] and is independent on 
maintaining stemness of MSCs during their in vitro 
expansion [29], suggesting that OCT4 is less likely to be 
regulated during the long-term passaging of MSCs in 
culture. Based on these results, RSV treatment can retain 
the protein abundance of SOX2 through a SIRT1-
dependent pathway and can also retain that of NANOG 
via the regulation of P53, but it does not affect the decline 
in the abundance of OCT4 during long-term passaging. 
Although it is a well-known SIRT1 activator, RSV 
also regulates diverse other proteins and signaling 
pathways in addition to SIRT1 [47]. In adipocytes, RSV 
modulates the PI3K/AKT and MAPK/ERK pathways in a 
SIRT1-independent manner, thus reducing the number 
and lipid accumulation of the adipocytes [48]. In addition,  
RSV was reported to induce cancer cell death via the 
ERK1/2-P53 axis [49]. It has been reported that the 
PI3K/AKT and ERK signaling pathways upregulate 
RUNX2 expression, finally resulting in tooth development 
and regeneration [50], which means that these signaling 
pathways are also involved in bone regeneration. In other 
words, the enhanced bone regeneration capacity of 6w-
MSCs with RSV induction could be associated with the 
regulation of other proteins and pathways by RSV in 
addition to its effect on SIRT1. In the present study, we 
did not confirm whether RSV treatment regulates other 
pathways such as PI3K, AKT, and ERK during the 
osteogenic differentiation of MSCs. However, our 
previous study revealed that the osteogenic differentiation 
potential of MSCs treated with RSV was abolished in 
SIRT1-deficient cells [12]. A recent study suggested that 
RSV stabilizes SIRT1/peptide interactions in a substrate-
specific manner [51], which means that RSV can directly 
bind to SIRT1 protein. In a previous study, we 
demonstrated that SIRT1 physically interacts with SOX2, 
and the direct interaction stabilizes SOX2 protein by 
deacetylating lysine residues in order to block the nuclear 
export and ubiquitination of SOX2 protein [16]. 
Collectively, RSV-activated signaling pathway is shown 
as direct interaction of RSV-SIRT1-SOX2 complex. In 
current study, we showed that RSV could not enhance the 
proliferation and differentiation potentials of MSCs 
without SIRT1 (Fig. 3G-3K). Likewise, our previous 
study also showed that RSV cannot enhance the 
proliferation and differentiation potentials of MSCs 
without SOX2 [16]; therefore, RSV-mediated 
enhancement of MSC function is shown to be directly 
involved with SIRT1-SOX2. In this study, we also 
confirmed the effect of RSV on maintaining multi-lineage 
differentiation potential of MSCs is mediated by SIRT1-
SOX2 axis, suggesting that the effect of RSV on bone 
regeneration may rely on the presence of SIRT1. 
The relationship between self-renewal, osteogenic, 
and adipogenic capacities of MSCs has been found to be 
antagonistic and competitive in various MSC-related 
studies. For this reason, many researchers may believe 
that enhancing the self-renewal capacity by some 
regulators or molecules enables suppression of stem cell 
differentiation, which means that undifferentiated state 
(no loss of differentiation potentials) of stem cells can be 
achieved by maintaining the self-renewal capacity of stem 
cells. Since MSC osteogenesis and adipogenesis are also 
shown to be competitive in differentiation condition, it 
can be thought that enhancing the osteogenic capacity of 
MSCs by some regulators or molecules enables  
suppression of the adipogenic potential of MSCs. 
However, various factors or proteins may be involved in 
the RSV-mediated enhancement of MSC self-renewal and 
differentiation potentials. RSV can mainly activate SIRT1 
to maintain the self-renewal and differentiation capacities 
in human MSCs [16]. The SIRT1 activated by RSV can 
affect MSC self-renewal-related regulators, such as SOX2 
[16] and FOXO3A [52], and MSC osteogenesis-related 
regulators, such as RUNX2 [53] and Wnt/β-catenin [54]. 
Some studies suggested that RSV decreased adipocyte 
differentiation and lipid accumulation in 3T3-L1 cells  
preadipocytes [55, 56], resulting in loss of body weight 
[57]. Collectively, it has been shown that RSV positively 
regulates MSC self-renewal and osteogenesis while 
negatively regulating MSC adipogenesis. However, the 
current study showed that RSV enhanced MSC 
adipogenic potential as well as the self-renewal and 
osteogenic potentials. These results can be explained by 
the fact that RSV-activated SIRT1 works in the cells by 
removing acetyl groups from protein substrates related to 
aging processes of MSCs in order to delay or prevent 
cellular aging. Delaying or preventing MSC aging by 
applying RSV in vitro enables gathering of healthy MSCs, 
which have self-renewal and multi-differentiation 
potentials during long-term cultivation. This means that in 
vitro RSV treatment maintains healthy MSCs over long-
term cultivation, thereby resulting in better proliferation 
Choi Y., et al                                                                                             MSC-Driven Bone Healing by RSV Treatment 
Aging and Disease • Volume 10, Number 4, August 2019                                                                               831 
 
and differentiation potentials compared to the cells  
cultured without RSV. It can also be thought that RSV 
suppresses in vivo adipogenesis of MSCs if proper 
materials with RSV can be applied into in vivo models; 
however, we could not confirm the in vivo effect of RSV 
on MSC adipogenesis as this study aimed to confirm 
whether RSV-treated MSCs had higher therapeutic 
potential when cells were transplanted into in vivo bone 
defect model. In this study, RSV effect in vivo refers to 
the bone regenerative capacity of MSCs pre-treated with 
RSV for long-term duration (6w-MSCs) in a rat calvarial 
defect model. We wanted to confirm whether bone 
regenerative potential of MSCs after the in vitro long-term 
cultivation for obtaining MSCs with effective cell doses 
could be preserved when the cells were cultured in RSV-
containing culture medium. It is important to gather the 
number of cells with effective dosage for MSC therapy; 
however, after passaging during long-term culture, most 
of the bone marrow-derived MSCs lose their potential to 
differentiate into multiple lineages as well as self-renewal 
capacity. Although RSV treatment is known to activate 
MSC proliferative and differentiation potentials, there is  
still not enough evidence to confirm whether RSV-treated 
MSCs are indeed effective in tissue regeneration when 
transplanted into in vivo disease models. Although RSV 
was treated with MSC cultures in this study, we believe it 
is possible for RSV to be injected into some disease 
models if appropriate materials are available for bone 
defects. This study provides a possibility that natural 
small molecules, such as RSV, can be employed in MSC 
culture in order to enhance therapeutic potential of cells. 
Therefore, we suggest that using small molecules would 
offer more benefits than using growth factors to enhance 
MSC stemness. 
Comprehensively, our study demonstrates that RSV 
treatment can enhance proliferation of MSCs and 
maintain differentiation potential during long-term 
expansion in vitro, and transplantation of MSCs pre-
treated with RSV improves bone regeneration in rat 
calvarial defect model. Although we transplanted MSCs 
mixed with fibrin glue for MSC delivery in vivo, 
examining alternative materials to provide the best 
environments for cell adherence, differentiation into 
cartilage, and effective delivery may facilitate more 
effective tissue regeneration. 
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